Results 101 to 110 of about 22,913 (185)

Letrozole removal resulted in testosterone and LH levels similar to placebo female mice.

, 2019
Schematic of study design: female mice were implanted with placebo or letrozole pellets at 4 weeks of age (week 0) and the pellets were removed at 9 weeks of age (week 5) (A).
Bryan S. Ho (7444598), Lillian Sau (6468299), Scott T. Kelley (7444601), Varykina G. Thackray (7444604), Pablo Arroyo (316123)   +4 more
core   +1 more source

Vaginal Laser Treatment for Genitourinary Syndrome of the Menopause: A Dose‐Determining Study in Breast Cancer Survivors

Lasers in Surgery and Medicine, Volume 58, Issue 9, Page 846-854, November 2026.
ABSTRACT Objectives Breast cancer survivors (BCSs) receiving endocrine therapy frequently develop genitourinary syndrome of menopause, characterized by vaginal dryness, pain, and urinary symptoms. Fractional CO2 vaginal laser therapy has been proposed as a non‐hormonal management option, but the optimal number of treatment sessions remains unclear.
Sine Jacobsen, Marianne Glavind‐Kristensen, Anders Bonde Jensen, Axel Forman, Vibe Munk Bertelsen, Pinar Bor   +5 more
wiley   +1 more source

Use of letrozole and clomiphene citrate combined with gonadotropins in clomiphene-resistant infertile women with polycystic ovary syndrome: a prospective study

, 2015
Wenyan Xi,1 Shankun Liu,2 Hui Mao,1 Yongkang Yang,1 Xiang Xue,1 Xiaoning Lu1 1The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an City, Shaanxi, 2Taian City Central Hospital, Shandong, Taian, People’s Republic of  ...
Xi W, Yang Y, Lu X, Mao H, Liu S, Xue X
core  

Angioneurotic edema of metastatic breast cancer patient associated with letrozole

, 2017
Breast cancer is the most frequent cancer in women leading to a Significant morbidity and mortality. The majority of breast malignancies are hormone responsive.
Ali Murat Sedef, BAKKAL TEMİ, YASEMİN, SEDEF, ALİ MURAT, Yasemin Bakkal Temi   +3 more
core   +1 more source

Microbial and Metabolic Correlates of Endometrial Dysfunction in Polycystic Ovary Syndrome: A Translational Study

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 12, Page 2092-2102, November 2026.
ABSTRACT Objective Women with polycystic ovary syndrome (PCOS) exhibit a substantially increased risk of miscarriage, yet the underlying mechanisms remain inadequately understood. This study aimed to investigate whether specific gut microbial dysbiosis and metabolic disturbance are associated with and may potentially contribute to endometrial ...
Mengyu Jing, Xi Chen, Meiyan Jiang, Huiya Fang, Xiaoming Zhu, Xuejing Jin, Yonghui Jiao, Ningning Hou, Weiwei Gong, Aixia Liu   +9 more
wiley   +1 more source

Polyendocrine Metabolic Ovarian Syndrome and the Entire Spectrum of Gestational Dysglycemia: A Population‐Based Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10122-10130, November 2026.
ABSTRACT Aims Evaluating the association between polyendocrine metabolic ovarian syndrome (PMOS), traditionally termed polycystic ovary syndrome, and the broad spectrum of gestational dysglycemia in a large, universally screened population. Materials and Methods This retrospective cohort study used routinely collected data linked from Israeli military ...
Yulia Balmakov, Maya Nitecki, Hertzel C. Gerstein, Orit Pinhas‐Hamiel, Gabriel Chodick, Estela Derazne, Yael Barer, Noah Gruber, Aya Bardugo, Cole D. Bendor, Avi Shina, Arnon Afek, Tali Cukierman‐Yaffe, Gilad Twig, Adi Vinograd   +14 more
wiley   +1 more source

A KATing Edge Perspective on KAT6A Inhibitors as Anticancer Agents

ChemMedChem, Volume 21, Issue 20, 28 October 2026.
This perspective efficiently summarizes the development of lysine acetyltransferase (KAT) inhibitors as anticancer agents, and the most clinically advanced KAT6A inhibitor, prifetrastat, entered Phase III clinical trials in 2025. KAT6A structural biology and structure activity relationships for acylsulfonylhydrazides, [1,2,4]thiadiazines, and ...
Rochelle Woodland, Adi Suwandi, Awgichew Behaile Teklemariam, Nidhish Francis, Li Li, Kenneth A. Chinkwo, Jonathan B. Baell, David J. Leaver   +7 more
wiley   +1 more source

Letrozole: A Steroid-Free Estrous Synchronization Method [PDF]

, 2018
Most bovine estrous synchronization protocols utilize progesterone plus estrogen to control ovulation timing. A drug that inhibits estrogen production (Letrozole) may be an alternative, steroid-free synchronization method (not yet commercially available).
Kurz, Scott G., Davis, John S., Wood, Jennifer R., Cupp, Andrea S., Romereim, Sarah M., Abedal-Majed, Mohamed A., Majed, Bergman, Jeffrey W., Tenley, Sarah C.   +7 more
core  

The Efficacy of Letrozole Co-Treatment in an Antagonist Protocol for Women with Polycystic Ovary Syndrome Undergoing IVF: A Retrospective Study [PDF]

Jing Lin,1 Fenglu Wu,2 Yanwen Zhu,2 Qianqian Zhu,2 Tong Du,2 Jiaying Lin2 1Center for Reproductive Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Assisted Reproduction ...
Zhu Y, Du T, Lin J, Wu F, Zhu Q
core  

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

, 2009
International audiencePURPOSE: Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor
Mark Pegram, Steven Stein, Pippen, John, Cristina Oliva, Press, Michael, F., Gilles Romieu, Alexey Manikhas, Lisa O'Rourke, Pivot, Xavier, B., Veronique Dieras, Stein, Steven, Pegram, Mark, Dieras, Veronique, O'Rourke, Lisa, Maltzman, Julie, John Pippen, Xavier Pivot, Allison Florance, Romieu, Gilles, Oliva, Cristina, M. John Kennedy, Kennedy, M John, Sadeghi, Saeed, Florance, Allison, Manikhas, Alexey, Henry Leonidas Gomez, Saeed Sadeghi, Stephen Johnston, Johnston, Stephen, Lichinitser, Mikhail, Gomez, Henry Leonidas, Mikhail Lichinitser, Julie Maltzman, Michael F. Press   +33 more
core   +1 more source